J E Polifka
Affiliation: University of Washington
- Developmental toxicity of ribavirin/IFalpha combination therapy: is the label more dangerous than the drugs?Janine E Polifka
Birth Defects Res A Clin Mol Teratol 67:8-12. 2003
- Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidenceJanine E Polifka
Department of Pediatrics, University of Washington, Seattle, Washington, USA
Birth Defects Res A Clin Mol Teratol 94:576-98. 2012....
- Developmental toxicity: web resources for evaluating risk in humansJanine E Polifka
Department of Pediatrics, TERIS Project, University of Washington, PO Box 357920, Seattle, WA 98195 7920, USA
Toxicology 173:35-65. 2002....
- Teratogen update: azathioprine and 6-mercaptopurineJanine E Polifka
TERIS Project, University of Washington, Seattle 98195 7920, USA
Teratology 65:240-61. 2002
- Medical genetics: 1. Clinical teratology in the age of genomicsJanine E Polifka
Department of Pediatrics, University of Washington, Seattle, USA
CMAJ 167:265-73. 2002..We discuss general principles of risk counselling and risk reduction, and we describe several long-known teratogens, as well as several exposures recognized only recently to have teratogenic potential...
- Postmarketing surveillance for human teratogenicity: a model approachC D Chambers
Department of Pediatrics, University of California, San Diego, CA 92103 8446, USA
Teratology 64:252-61. 2001..The purpose of this report is to outline a complementary approach that can be used in addition to other more established methods to provide the most comprehensive evaluation of prenatal exposures with respect to teratogenicity...
- Update on new developments in the study of human teratogensT H Shepard
University of Washington, Department of Pediatrics, Seattle, Washington 98195 6320, USA
Teratology 65:153-61. 2002..The purpose of this annual article is to highlight and briefly review new and significant information on agents that may be teratogenic in pregnant women. Various sources of on-line and printed information are given...
- Drug safety in pregnant women and their babies: ignorance not blissC D Chambers
Department of Pediatrics, University of California, San Diego School of Medicine, La Jolla, California, USA
Clin Pharmacol Ther 83:181-3. 2008....
- Addendum: sartan treatment during pregnancySura Alwan
Department of Medical Genetics, University of British Columbia, Vancouver, Canada
Birth Defects Res A Clin Mol Teratol 73:904-5. 2005
- A survey of pregnant women using isotretinoinJulia Robertson
Utah Department of Health, Division of Community and Family Health Services, Birth Defects and Genetics Program, Pregnancy RiskLine, Salt Lake City, 84114 4691, USA
Birth Defects Res A Clin Mol Teratol 73:881-7. 2005..Isotretinoin is a known human teratogen, causing birth defects and/or subnormal cognitive performance in prenatally-exposed children...
- Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseasesJoseph Lam
Department of Pediatrics, Division of Dermatology, Rady Children s Hospital, University of California, San Diego, California, USA
J Am Acad Dermatol 59:295-315. 2008..In addition, a list of teratology information resources is included to help practicing clinicians find up-to-date information regarding the safety of the medications they prescribe...